Subscribe To

Price Alert Latest News Economic Calendar News

AWKNF / Awakn Life Sciences currently undervalued say Stifel analysts noting de-risked Phase 3 ketamine trial and clinic momentum

Awakn Life Sciences Corp (NEO:AWKN), a biotechnology company developing psychedelic therapies to treat addiction with a near-term focus on alcohol use disorder (AUD), is at an ideal entry point for investors given the company's de-risked ketamine Phase 3 trial for AUD in the UK as well as good momentum in its clinics, according to analysts at Stifel GMP. In a note to clients, the analysts wrote that Awakn has progressed on multiple fronts, such as securing a differentiated partnership with the UK government to conduct its Phase 3 pivotal trial, Project Kestrel, for ketamine for severe AUD across seven NHS sites. Read More

Demo Live Account See Partner Details

Content Topics

Awakn

Life

Sciences

Currently

Undervalued

Stifel

Analysts

Noting

De risked

Ketamine

Clinic

Momentum

Stock

AWKNF

Posted: Dec 19 2022, 14:46

Author Name: Proactive Investors

AWKNF News

By Proactive Investors
December 19, 2022

Awakn Life Sciences currently undervalued say Stifel analysts noting de-risked Phase 3 ketamine trial and clinic momentum

Awakn Life Sciences Corp (NEO:AWKN), a biotechnology company developing psychedelic therapies to treat addiction with a near-term focus on alcohol use

By Benzinga
April 4, 2022

Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades o

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.